Back

Prognostic importance of NT-proBNP following high-risk myocardial infarction in the PARADISE-MI Trial

26 August 2022 (14:50 - 15:00)
Organised by:
Congress Presentation Part of: Troponin and other biomarkers in acute coronary syndromes Epidemiology, Prognosis, Outcome ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Karola Jering

Brigham and Women's Hospital, Boston (United States of America)

5 More presentations in this session

Presentation thumbnail
Extending the no objective testing rules to patients triaged by the ESC 0/1-hour algorithms
Doctor J. Boeddinghaus (Basel, CH)
Abstract Slides Video
Presentation thumbnail
Cardiac troponin elevation and mortality in takotsubo syndrome: new insights from the international takotsubo (InterTAK) registry
Professor B. Stahli (Zurich, CH)
Abstract Slides Video
Presentation thumbnail
Impact of time from symptom onset on the diagnostic performance of high-sensitivity cardiac troponin for type 1 myocardial infarction
Doctor M. Lowry (Edinburgh, GB)
Abstract Slides Video
Presentation thumbnail
High-sensitivity troponin is a biomarker of medium term mortality in 20,000 consecutive hospital patients undergoing a blood test for any reason
Doctor J. Hinton (Bournemouth, GB)
Abstract Slides Video
Presentation thumbnail
Implementation of high-sensitivity cardiac troponin and risk of myocardial infarction or death at 5 years: a stepped-wedge cluster-randomised controlled trial
Doctor K. Lee (Edinburgh, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Troponin and other biomarkers in acute coronary syndromes

The Event

Event poster

ESC Congress 2022

26 August 2022 14:50 CET
You may be interested in
thumbnail
Congress Session
Biomarkers definning pathophysiology and prognosis
thumbnail
Congress Session
Advancing cardiovascular medicine through novel applications of cardiac biomarkers
thumbnail
Congress Presentation
Utility of NT-proBNP for detecting heart failure and assessing prognosis in elderly myocardial infarction survivors: insights from the OMEMI trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources